Farudodstat, Farudodstat’s R&D Progress, Mechanism of Action for Farudodstat, drug target for Farudodstat.
This article summarized the latest R&D progress of Farudodstat, the Mechanism of Action for Farudodstat, and the drug target R&D trends for Farudodstat.
Farudodstat‘s R&D Progress
Farudodstat is a small molecule drug that targets DHODH, an enzyme involved in the synthesis of pyrimidine nucleotides. It has shown potential therapeutic benefits in various therapeutic areas including infectious diseases, respiratory diseases, immune system diseases, nervous system diseases, digestive system disorders, skin and musculoskeletal diseases, and neoplasms.
The drug has demonstrated activity against several indications, including Alopecia Areata, Acute Myeloid Leukemia, Inflammatory Bowel Diseases, Skin Diseases, Autoimmune Diseases, Multiple Sclerosis, Rheumatic Fever, COVID-19, Zika Virus Infection, and Dengue. This broad range of indications suggests that Farudodstat may have a diverse mechanism of action or a wide spectrum of activity.
Farudodstat is currently in Phase 2 of clinical development. The drug is being developed by Almirall SA, a pharmaceutical company specializing in dermatology and respiratory diseases.
Given the wide range of therapeutic areas and indications targeted by Farudodstat, it has the potential to address unmet medical needs in various disease areas. However, it is important to note that the information provided is limited, and further research and clinical trials are needed to fully understand the drug’s efficacy, safety profile, and potential commercial viability.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Farudodstat: DHODH inhibitors
DHODH inhibitors are a type of drug that target and inhibit the enzyme dihydroorotate dehydrogenase (DHODH). DHODH is an essential enzyme involved in the de novo synthesis of pyrimidine, which is a building block for DNA and RNA. By inhibiting DHODH, these inhibitors disrupt the production of pyrimidine, leading to a decrease in DNA and RNA synthesis.
From a biomedical perspective, DHODH inhibitors have shown potential as therapeutic agents in the treatment of various diseases, particularly in the field of oncology. Cancer cells often have increased demands for nucleotides, including pyrimidines, to support their rapid proliferation. By blocking DHODH, these inhibitors can selectively target cancer cells that rely heavily on de novo pyrimidine synthesis, while sparing normal cells that can obtain pyrimidines through salvage pathways.
DHODH inhibitors have been investigated for their potential in treating cancers such as acute myeloid leukemia (AML), lymphoma, and solid tumors. In preclinical and clinical studies, these inhibitors have demonstrated anti-tumor activity and have shown promise as a targeted therapy.
It is important to note that DHODH inhibitors can have side effects, as they may also affect normal cells that rely on de novo pyrimidine synthesis. Therefore, careful evaluation of their therapeutic index and potential toxicity is necessary in the development and use of these inhibitors as drugs.
Drug Target R&D Trends for Farudodstat
DHODH, or dihydroorotate dehydrogenase, is an essential enzyme involved in the de novo synthesis of pyrimidine nucleotides, which are building blocks of DNA and RNA. Found in the mitochondria, DHODH catalyzes the conversion of dihydroorotate to orotate, a crucial step in the production of pyrimidines. By regulating the availability of pyrimidine nucleotides, DHODH plays a vital role in cell proliferation, growth, and division. Due to its significance in DNA and RNA synthesis, DHODH has emerged as a potential target for therapeutic intervention in various diseases, including cancer, autoimmune disorders, and viral infections.
According to Patsnap Synapse, as of 26 Sep 2023, there are a total of 35 DHODH drugs worldwide, from 56 organizations, covering 57 indications, and conducting 228 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
In summary, Farudodstat is a small molecule drug targeting DHODH, with potential applications in infectious diseases, respiratory diseases, immune system diseases, nervous system diseases, digestive system disorders, skin and musculoskeletal diseases, and neoplasms. It is currently in Phase 2 of clinical development and is being developed by Almirall SA. Further research and clinical trials are required to determine its full therapeutic potential.